ERS 2026: Phase Ib/IIa results support further evaluation of 9MW1911 in COPD

Phase 2positive9MW1911Positive

AI Analysis

Summary

Arano Pharmaceuticals presented Phase Ib/IIa results for 9MW1911 in COPD at ERS 2026, with data supporting further clinical evaluation. The results provide clinical validation for IL-33/ST2 as a therapeutic target in COPD.

Clinical Trial Data

Phase

Ib/IIa

Primary Endpoint

Met

Outcome Details

Phase Ib/IIa results support further evaluation of 9MW1911 in COPD

Importance:6/10

Sentiment:

0.70

Phase 2 dataCOPDIL-33/ST2 axisERS 2026clinical trial results

Related Companies

$ARNA

Read the original article

Published by Clinical Trials Arena on September 10, 2026 4:06 PM

Read Original